信达证券发布天士力研报，华润融合顺利推进，创新研发价值重估

Group 1 - The pharmaceutical industry remains stable, with a reclassification of product categories [2] - The integration with China Resources is progressing smoothly, which is expected to bring positive changes [2] - The research and development pipeline is rich, indicating a potential for value reassessment [2]